头孢丙烯在下呼吸道细菌感染患者的药代动力学研究

The pharmacokinetics study of cefprozil in patients with low respiratory tract bacterial infections

目的:通过研究下呼吸道细菌感染患者的头孢丙烯临床药代动力学参数,为临床选择合理给药方案提供依据。方法:用HPLC法测定10例下呼吸道细菌感染患者连续给药5d后的稳态血药浓度,数据用3P97 药物动力学模拟系统处理。结果:头孢丙烯的药时曲线符合二室开放模型,主要药代动力学参数:t1/2为 (1．55±0．17)h,MRT为(2．52±0．15)h,Cmax为(13．32±1．28)μg／mL,tmax为(1．41±0．31)h,AUC0-10为 (31．68±7．68)μg h／mL。结论:口服头孢丙烯片500mg,每天2次,能获得控制下呼吸道细菌感染的有效治疗浓度。

Objective：To offer the evidence for reasonable dosage regimen by the pharmacokineties study of cefprozil in patients with low respiratory tract hacterial infections. Methods：The cefprozil concentration in plasma was determined by the high performance liquid chromatography method, The pharmaeokinetic parameters were obtained by using 3P97 imitate program. Results：With oral multipie - dose of 500mg of cefprozil twice over 5 consecutive days, the main pharmacokinetic parameters obtained from the patients were as follows：t1/2 was （ 1.55 ±0.17）h ,MRT was （2.52 ±0.15） h,Cmax , was （ 13.32 ± 1.28） μg/mL,t was （ 1.41 ±0.31 ）h ,AUC0-10 was （ 31.68 ± 7.68） μg · h/mL. Conclusions： Conclusions 500mg, hid orally may be effective against low respiratory tract bacterial infect infcctions.